ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect ProQR Therapeutics to post earnings of ($0.08) per share and revenue of $6.1180 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 12:30 PM ET.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $1.70 on Thursday. The stock has a market capitalization of $178.86 million, a P/E ratio of -3.62 and a beta of 0.21. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $3.10. The stock has a 50-day simple moving average of $1.68 and a 200 day simple moving average of $2.08.

Institutional Trading of ProQR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC lifted its holdings in shares of ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 79,720 shares during the last quarter. Bank of America Corp DE raised its stake in ProQR Therapeutics by 25.7% during the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 24,347 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in ProQR Therapeutics by 28.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 26,893 shares during the period. Osaic Holdings Inc. grew its position in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of ProQR Therapeutics by 86.3% during the 3rd quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 193,260 shares during the period. 32.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Zacks Research raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.14.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.